Hexima Ltd (HXL)

HXL Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 9-day 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 6m 1yr 5yr 10yr

HXL's Principal Activity is the research and development of plant-derived proteins and peptides for applications as human therapeutics.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Mr Steven Michael Skala	Alternate Director	Mar 2020	Mr Steven Michael Skala Alternate Director Mr Skala is Vice Chairman, Australia and New Zealand of Deutsche Bank AG. He retired from legal practice after almost 25 years experience in commercial law. Between 1985 and 2004 he was a partner of law firm, Arnold Bloch Leibler, and was Head of its Corporate and Commercial Practice for several years. He is a Director of the Australian Broadcasting Corporation, Deutsche Australia Limited, Wilson HTM Investment Group Limited, and The Centre for Independent Studies and he is Deputy Chairman of the General Sir John Monash Foundation. He is also Vice President of The Walter and Eliza Hall Institute for Medical Research and was previously Chairman of Film Australia Limited and The Australian Centre for Contemporary Arts and a director of Max Capital Group Limited and The Australian Ballet.
Mr Michael Douglas Aldridge	Chief Executive Officer,Managing Director	May 2019	Mr Michael Douglas Aldridge Chief Executive Officer,Managing Director Mr Aldridge most recently served as Senior Vice President, Corporate & Strategic Development of Codexis from October 2016 until August 2018. Prior to that, from January 2012 to September 2014, he served as Senior Vice President, Corporate Strategic Development for Questcor Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals in 2014. From May 2010 to September 2012, Mr Aldridge served as Chief Executive Officer and a member of the board of directors for Xenome Limited, a privately-held biopharmaceutical company headquartered in Australia. Between 2003 and 2009, he served as Chief Executive Officer and a member of the board of directors and a strategic consultant of Peplin, Inc., a publicly-traded drug development company acquired by LEO Pharma A/S in 2009. Prior to that, he held investment banking positions at various financial firms, including Wilson HTM Investment Group, Bear, Stearns & Co., Volpe, Brown, Whelan & Company and S.G. Warburg Group.
Mr Scott Christian Robertson	Non-Executive Director	Nov 2018	Mr Scott Christian Robertson Non-Executive Director Mr Robertson is currently Chief Financial Officer at DiCE Molecules. Prior to DiCE Molecules, he served at DuPont where he was Business Development Director for DuPont Pioneer with responsibility for the business unit's crop genetics and precision agriculture M&A activity. He also held the position of portfolio manager with DuPont Ventures where he focused on strategic investment opportunities in production agriculture and the intersection of agriculture and downstream renewable technologies. Prior to joining DuPont, he was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and before that a member of the Healthcare Investment Banking groups at Merrill Lynch & Co. and Thomas Weisel Partners. He is also a member of Risk Committee.
Mr Justin Zhen Nan Yap	Non-Executive Director	Jul 2018	Mr Justin Zhen Nan Yap Non-Executive Director Mr Yap is a Non-Executive Director of CathRx Limited, an Australian medical device company commercialising cardiac electrophysiology catheters for the treatment of heart rhythm disorders. He is a Non-Executive Director of Wilhelm Integrated Solutions Pty Ltd, a distributor of integrated operating room technology to hospitals around Australia. Prior to this, he began his career in investment banking for Mosaic Risk Management Pty Ltd, a wholly owned subsidiary of Wilson HTM Limited specialising in derivatives risk management. He s also a member of Risk Committee.
Dr Nicole Louise van der Weerden	Chief Operating Officer,Executive Director	Dec 2014	Dr Nicole Louise van der Weerden Chief Operating Officer,Executive Director Dr van der Weerden has experience as she has led the gene discovery program for the Pioneer partnership on control of fungal diseases in corn. She led the Hexima team that identified the clinical opportunities for plant antifungal molecules and discovered and developed HXP124 for treatment of onychomycosis. He is also an inventor on nine patent applications. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006.
Professor Marilyn Ann Anderson	Chief Science Officer,Executive Director	Nov 2010	Professor Marilyn Ann Anderson Chief Science Officer,Executive Director Professor Anderson has over 40 years of experience in scientific research in the area of biochemistry and genetics. After completing a BSc Honours at The University of Melbourne and a PhD in Biochemistry at La Trobe University, Professor Anderson spent seven years in the United States working on diabetes at the University of Miami Florida, and molecular biology at Cold Spring Harbor Laboratory NY. She is an expert on antifungal and insecticidal molecules produced by plants. She is a Professor of Biochemistry at La Trobe University, and a member of the Australian Academy of Science Council. She was appointed an Officer of the Order of Australia in 2016 for distinguished service to science and higher education. She was a member of the La Trobe Council until 2017.
Professor Jonathan Paul West	Non-Executive Director,Non-Executive Chairman	Nov 2005	Professor Jonathan Paul West Non-Executive Director,Non-Executive Chairman Professor West was the founding Director of the Australian Innovation Research Centre. Prior to that, he taught for 18 years at the Harvard University Graduate School of Business Administration, where he was Associate Professor, founding Director of the Harvard University Life Sciences Initiative, and from 1998-1999 the Novartis Faculty Research Fellow. He has been Visiting Professor at Hitotsubashi University and the Nomura School of Advanced Management in Tokyo, Japan and Visiting Professor at the University de Paris IX-Dauphine, Sorbonne. Professor West was Chairman of the Asia Advisory Council of Bunge Ltd and has served as an advisor to other corporations and several Governments around the world, including in the life sciences field DuPont, Roche, Novartis, Syngenta and the J.R. Simplot Company, along with the Governments of Singapore, Japan, Hong Kong and France. He was a member of the Scientific Advisory Board of the Novartis Agricultural Discovery Institute in La Jolla, California. In Australia, he has served on the Prime Minister's Science, Engineering, Innovation Council's Working Group on Science and Technology in China and India and in 2006 was 'Eminent Thinker in Residence' with the Premier of NSW. Professor West is the non-executive chairman of Gowing Bros Limited and non-executive director of Boundary Bend Limited and the Hydration Pharmaceuticals Company Limited. He is also the Chairman of Risk committee.
Ms Helen Molloy	Company Secretary,Finance Controller	N/A
Marilyn A Anderson	Chief Science Officer	N/A
Robyn L Heath	Senior Vice President Product Development	N/A

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Steven Skala	10/03/2020	4,167,467	5,480,029	125,000	N/A
Michael Aldridge	21/05/2019	N/A	N/A	2,750,000	N/A
Scott Robertson	21/11/2018	N/A	N/A	312,500	N/A
Justin Yap	17/07/2018	N/A	N/A	312,500	N/A
Nicole van der Weerden	16/12/2014	144,700	N/A	1,650,000	N/A
Marilyn Anderson	23/11/2010	2,280,548	N/A	250,000	N/A
Jonathan West	27/08/2010	2,000,000	N/A	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Dato Lim Sen Yap	14,715,790	11.25%
Caroline House Superannuation Fund Pty Ltd (Caroline House S/F A/C)	8,287,131	6.33%
Woobinda Nominees Pty Ltd (The Woobinda Family A/C)	6,372,222	4.87%
Beta Gamma Pty Ltd (Walsh Street Super Fund A/C)	5,736,586	4.38%
Gowing Bros Limited	4,256,176	3.25%
Paul Orlin	3,750,000	2.87%
Gowing Bros Ltd	3,667,131	2.80%
HSBC Custody Nominees (Australia) Limited	3,496,219	2.67%
Balmoral Financial Investments Pty Ltd	3,051,090	2.33%
Adrienne Clarke	3,028,938	2.31%
Hugh Morgan	2,977,252	2.28%
Dalit Pty Ltd (Dalit Family A/C)	2,500,000	1.91%
Dongrisha Pty Ltd (The Dongrisha Investment A/C)	2,500,000	1.91%
Huysmans Pty Ltd (The Lama A/C)	2,346,011	1.79%
Marilyn Anderson	2,280,548	1.74%
Saxum Pty Ltd	2,106,755	1.61%
Cranley Nominees Pty Ltd (Fitzroy Family A/C)	2,007,674	1.53%
Pioneer Hi-Bred International Inc.	2,000,000	1.53%
Andama Holdings Pty Ltd (J & M Barlow Pension A/C)	1,851,057	1.41%
Mr Leon Francis Lachal & Mrs Susan Margaret Lachal (The Lachal Super Fund A/C)	1,779,249	1.36%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

HXL Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.